Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 10/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20258903 | 0.86 | GABRA1 (0.48) | GABRA1GABRA5KCNH2GPBAR1PIK3CA | |
| SCHEMBL21590459 | 0.81 | GABRA1 (0.52) | GABRA1 | |
| SCHEMBL30062683 | 0.81 | GABRA1 (0.52) | GABRA1 | |
| SCHEMBL5775028 | 0.80 | GABRA5 (0.52) | GABRA5CASP3GPBAR1 | |
| SCHEMBL21590958 | 0.80 | GABRA1 (0.45) | GABRA1GABRA5CASP3 | |
| SCHEMBL27116797 | 0.79 | GABRA5 (0.41) | GABRA1GABRA5 | |
| SCHEMBL21590852 | 0.78 | GABRA1 (0.40) | GABRA1GABRA5CASP3GPBAR1 | |
| SCHEMBL21590867 | 0.77 | GABRA5 (0.34) | GABRA1GABRA5 | |
| SCHEMBL286512 | 0.75 | GABRA5 (0.49) | GABRA5KCNH2GPBAR1 | |
| SCHEMBL21590814 | 0.75 | GABRA1 (0.50) | GABRA1GABRA5PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637455-B2 | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as GABAA α5 receptor modulators | RICHTER GEDEON NYRT. (HU) | 2026-05-26 | — | — | US | disclosed |
| US-20250051323-A1 | BICYCLIC AMINE DERIVATIVES AS GABAA alpha5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT. (HU) | 2025-02-13 | — | — | US | disclosed |
| EP-4408842-A1 | BICYCLIC AMINE DERIVATIVES AS GABAA a5 RECEPTOR MODULATORS | Richter Gedeon Nyrt. (HU) | 2024-08-07 | — | — | EP | disclosed |
| CN-118284606-A | Bicyclic amine derivatives as GABAA α5 receptor modulators | 吉瑞工厂 | 2024-07-02 | — | — | CN | disclosed |
| US-20240067637-A1 | NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA ALPHA 5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT. (HU) | 2024-02-29 | — | — | US | disclosed |
| US-20240067637-A1 | NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA ALPHA 5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT. (HU) | 2024-02-29 | — | — | US | disclosed |
| US-20240067637-A1 | NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA ALPHA 5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT. (HU) | 2024-02-29 | — | — | US | disclosed |
| US-11840528-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-12-12 | — | — | US | disclosed |
| WO-2023053015-A1 | BICYCLIC AMINE DERIVATIVES AS GABAA α5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT. (HU) | 2023-04-06 | — | — | WO | disclosed |
| EP-4126859-A1 | NAPHTHYRIDINE AND PYRIDO[3,4-C]PYRIDAZINE DERIVATIVES AS GABAA ALPHA5 RECEPTOR MODULATORS | Richter Gedeon Nyrt. (HU) | 2023-02-08 | — | — | EP | disclosed |
| CN-115348962-A | As GABA A Naphthyridines and pyrido [3,4-c ] of alpha 5 receptor modulators]Pyridazine derivatives | 吉瑞工厂 | 2022-11-15 | — | — | CN | disclosed |
| WO-2021191838-A1 | NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA α5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT. (HU) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021191838-A1 | NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA α5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT. (HU) | 2021-09-30 | — | — | WO | disclosed |
| EP-3807269-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | F. Hoffmann-La Roche AG (CH) | 2021-04-21 | — | — | EP | disclosed |
| US-20210094945-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2021-04-01 | — | — | US | disclosed |
| CN-112424196-A | Novel isoxazolyl ether derivatives as GABAA alpha 5 PAM | 豪夫迈·罗氏有限公司 | 2021-02-26 | — | — | CN | disclosed |
| WO-2019238633-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | F. HOFFMANN-LA ROCHE AG (CH) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840528-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | GABRA5, GABRA2, GABRB2 | GABRA1 4/4885GABRA5 1/4885CASP3 3657/4885 |
| US-20210094945-A1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRB2, GABRB1 | GABRA1 4/4885GABRA5 1/4885CASP3 2836/4885 |
| US-12637455-B2 | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as GABAA α5 receptor modulators | GABRA5, GABRA1, GABRB1 | GABRA1 2/4885GABRA5 1/4885CASP3 3312/4885 |
| US-20240067637-A1 | NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA ALPHA 5 RECEPTOR MODULATORS | GABRA5, GABRA1, GABRA3 | GABRA1 2/4885GABRA5 1/4885CASP3 2279/4885 |
| US-20250051323-A1 | BICYCLIC AMINE DERIVATIVES AS GABAA alpha5 RECEPTOR MODULATORS | GABRA5, GABRB1, GABRA1 | GABRA1 3/4885GABRA5 1/4885CASP3 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.